Page 8 - hypertension_newsletter7
P. 8
REFLECTIONS
Hypertension
Hypertension Global Newsletter #7 2024
the seven trials included participants with diabetes. to <140 mmHg, there was a significant reduction in major CVD
events (HR, 0.82 [95% CI, 0.74–0.91]), but all-cause mortality
Intensive SBP lowering to a target of <130 mmHg significantly was marginally insignificant (HR, 0.85 [95% CI, 0.71–1.01]).
Hypertension
reduced the risk of major CVD compared with a target of ≥130 In addition to the overall CVD benefit, there was a significant
mmHg (HR, 0.78 [95% CI, 0.70–0.87]) and reduced the risk of reduction in stroke, coronary heart disease, heart failure, and
all-cause mortality (HR, 0.89 [95% CI, 0.79–0.99]). In a subset CVD mortality. Adverse events were significantly more likely in
of four studies that examined an SBP <120 mmHg compared the intensive SBP target groups, but the absolute risks were low.
Randomisation to more or less intensive SBP lowering on major CVD events
Randomisation to more or less intensive SBP lowering on all-cause mortality
TABLE OF CONTENTS
